Reports Q4 revenue $2.3M, consensus $3.2M. "Zevra is a company transformed, with a new strategic purpose to deliver novel therapeutics to patients with rare diseases," said Richard W. Pascoe, Chief Executive Officer of Zevra Therapeutics. "The Company is guided by a world-class leadership team and board of directors, and we are in a strong position to execute on multiple anticipated milestones during 2023 that should provide a springboard for continued value creation. The Company’s future is more promising than at any time in our history as we are primed to advance arimoclomol, our NDA-stage investigational product candidate for Niemann-Pick disease Type C, and KP1077, our lead clinical candidate for treatment for idiopathic hypersomnia, towards key regulatory and data events during the year. As we move Zevra forward, we will continue to leverage our legacy platform to target internally discovered rare disease product opportunities and to extend exclusivity of our pipeline assets through life cycle management."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ZVRA:
